ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy disorders. It is developing OBE2109, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age. The company was founded in 2012 and is headquartered in Plan-les-Ouates, Switzerland.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:OBSV
CUSIPN/A
Phone41-22-552-3840
Debt
Debt-to-Equity RatioN/A
Current Ratio8.35
Quick Ratio8.35
Price-To-Earnings
Trailing P/E Ratio-6.84
Forward P/E Ratio-7.00
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.30 per share
Price / Book4.66
Profitability
EPS (Most Recent Fiscal Year)($2.25)
Net Income$-66,920,000.00
Net MarginsN/A
Return on Equity-70.18%
Return on Assets-62.68%
Miscellaneous
Employees39
Outstanding Shares37,130,000
Obseva (NASDAQ:OBSV) Frequently Asked Questions
What is Obseva's stock symbol?
Obseva trades on the NASDAQ under the ticker symbol "OBSV."
How were Obseva's earnings last quarter?
Obseva SA (NASDAQ:OBSV) announced its earnings results on Wednesday, May, 16th. The company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.46) by $0.08. View Obseva's Earnings History.
When is Obseva's next earnings date?
What price target have analysts set for OBSV?
5 brokerages have issued 1 year price objectives for Obseva's stock. Their forecasts range from $18.00 to $31.00. On average, they expect Obseva's stock price to reach $23.40 in the next twelve months. View Analyst Ratings for Obseva.
What are Wall Street analysts saying about Obseva stock?
Here are some recent quotes from research analysts about Obseva stock:
- 1. HC Wainwright analysts commented, "We anticipate top-line data within the next few weeks from the Phase 2b EDELWEISS trial of OBE2109 (linzagolix), ObsEva’s main clinical-stage asset, in women with endometriosis. As a reminder, the broad goal of this study is the identification of two distinct therapeutic dosing options to serve the needs of the large and diverse endometriosis patient population: (1) a dosage with the potential for alleviating patient symptoms with moderate estrogen suppression that does not meaningfully decrease bone mineral density (BMD), thus obviating the need for hormonal add- back therapy (ABT); and (2), a higher dosage that fully or nearly fully suppresses estrogen, which would require ABT to restore estrogen with the purpose of counteracting bone loss." (6/11/2018)
- 2. According to Zacks Investment Research, "ObsEva SA is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics for woman's reproductive health and pregnancy. ObsEva SA is headquartered in Geneva, Switzerland. " (5/22/2018)
Who are some of Obseva's key competitors?
Some companies that are related to Obseva include Heron Therapeutics (HRTX), Akcea Therapeutics (AKCA), Spectrum Pharmaceuticals (SPPI), Global Blood Therapeutics (GBT), Puma Biotechnology (PBYI), Insmed (INSM), Endo International (ENDP), ACADIA Pharmaceuticals (ACAD), Prestige Brands (PBH), Akorn (AKRX), Phibro Animal Health (PAHC), Aimmune Therapeutics (AIMT), AnaptysBio (ANAB), PTC Therapeutics (PTCT) and Myokardia (MYOK).
Who are Obseva's key executives?
Obseva's management team includes the folowing people:
- Dr. Ernest Loumaye, Co-Founder, CEO & Director (Age 66)
- Mr. Timothy M. Adams, Chief Financial Officer (Age 58)
- Dr. Jean-Pierre Gotteland Ph.D., Chief Scientific Officer (Age 53)
- Mr. Mario Vincent Corso, Sr. Director of Investor Relations
- Dr. Elke Bestel M.D., Chief Medical Officer and Head of Pharmacovigilance (Age 52)
When did Obseva IPO?
(OBSV) raised $98 million in an IPO on Thursday, January 26th 2017. The company issued 6,500,000 shares at $14.00-$16.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO.
Has Obseva been receiving favorable news coverage?
Media stories about OBSV stock have trended somewhat negative recently, according to Accern. The research group scores the sentiment of news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Obseva earned a daily sentiment score of -0.06 on Accern's scale. They also gave news stories about the company an impact score of 46.77 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.
Who are Obseva's major shareholders?
Obseva's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Sofinnova Ventures Inc (12.79%), VHCP Management II LLC (5.77%), Sphera Funds Management LTD. (2.01%) and DRW Securities LLC (0.06%). View Institutional Ownership Trends for Obseva.
Which major investors are buying Obseva stock?
OBSV stock was purchased by a variety of institutional investors in the last quarter, including Sofinnova Ventures Inc, Sphera Funds Management LTD., VHCP Management II LLC and DRW Securities LLC. View Insider Buying and Selling for Obseva.
How do I buy shares of Obseva?
Shares of OBSV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Obseva's stock price today?
One share of OBSV stock can currently be purchased for approximately $15.39.
How big of a company is Obseva?
Obseva has a market capitalization of $540.26 million. The company earns $-66,920,000.00 in net income (profit) each year or ($2.25) on an earnings per share basis. Obseva employs 39 workers across the globe.
How can I contact Obseva?
Obseva's mailing address is Chemin des Aulx 12 Plan-les-Ouates, Geneva V8, 1228. The company can be reached via phone at 41-22-552-3840 or via email at [email protected]
MarketBeat Community Rating for Obseva (OBSV)
MarketBeat's community ratings are surveys of what our community members think about Obseva and other stocks. Vote "Outperform" if you believe OBSV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OBSV will underperform the S&P 500 over the long term. You may vote once every thirty days.
